
Has your bladder biopsy report mentioned high-grade urothelial carcinoma? You may be worried about how serious the diagnosis is, whether the cancer has spread and whether your bladder needs to be removed.
High-grade bladder cancer needs careful evaluation, but high-grade does not automatically mean that the cancer has invaded the bladder muscle.
Some high-grade tumours remain confined to the inner layers of the bladder and are classified as high-grade non-muscle-invasive bladder cancer (NMIBC). These tumours may require repeat resection, treatment placed directly into the bladder and close surveillance. In selected patients with a high risk of progression, early radical cystectomy may also need to be discussed.
Dr. Swati H. Shah is a uro-oncologist and robotic cancer surgeon in Ahmedabad with experience in bladder cancer surgery since 2008, including TURBT and major bladder cancer surgery.
The most important first step is to establish the exact tumour stage, identify high-risk features and determine which treatment offers the best balance between cancer control and quality of life.
Bladder cancer is classified according to its grade and stage. Grade describes how abnormal the tumour cells look under the microscope. Stage describes how deeply the cancer has grown into the bladder wall or whether it has spread beyond the bladder.
High-grade non-muscle-invasive bladder cancer includes certain high-grade tumours that have not invaded the bladder muscle. These may include:
These conditions are not identical. Their management depends on the pathological stage, tumour characteristics and other risk factors. High-grade T1 disease and carcinoma in situ require particular attention because they can carry a significant risk of progression.
High-grade bladder cancer is generally more likely to recur or progress than low-grade disease. However, the level of risk varies considerably between patients.
Important factors include:
A small high-grade Ta tumour and a high-grade T1 tumour with additional adverse features should not automatically be managed in the same way. The treatment plan must be based on the complete pathology report and the patient’s overall risk category.
If the pathology report is unclear or the findings are concerning, a specialist review of the slides and report may be appropriate.
Treatment is planned according to the exact stage and risk category. The main options may include TURBT, repeat TURBT, intravesical treatment, surveillance and, for selected high-risk patients, radical cystectomy.
Transurethral resection of bladder tumour (TURBT) is performed through the urinary passage using an endoscopic instrument. The visible tumour is removed, and the tissue is examined by a pathologist to determine the tumour grade, stage and other relevant features.
The purpose is not only to remove the visible tumour but also to obtain adequate information for treatment planning. For high-grade disease, the quality and completeness of the initial resection are particularly important.
Some patients with high-grade non-muscle-invasive bladder cancer need a second TURBT. Repeat resection may be recommended when:
A repeat TURBT allows the surgeon to assess the original tumour site, remove residual tumour when present and identify any under-staging. When indicated, repeat TURBT is commonly planned within approximately two to six weeks of the initial procedure, depending on the clinical circumstances.
Not every patient needs a second procedure. The recommendation should be based on the operative findings and pathology report.
After TURBT, some patients require treatment delivered directly into the bladder to reduce the risk of recurrence and progression.
BCG (Bacillus Calmette–Guérin) immunotherapy is an important treatment for appropriate patients with high-risk non-muscle-invasive bladder cancer. It is placed into the bladder through a catheter and stimulates a local immune response against bladder cancer cells.
For appropriate patients, BCG may be given as an induction course followed by maintenance treatment, according to the patient’s risk and treatment plan. Intravesical chemotherapy may be appropriate in certain situations, but the choice depends on the specific tumour and its risk category.
Intravesical treatment is not a substitute for adequate staging. The treating team must first determine whether the tumour remains non-muscle-invasive and whether bladder-preserving treatment is appropriate.
Radical cystectomy involves surgical removal of the urinary bladder, together with the appropriate associated procedures and regional lymph-node dissection.
Although many patients with non-muscle-invasive disease can be managed without bladder removal, early radical cystectomy should be discussed with selected patients who have very high-risk disease.
Features that may prompt this discussion include:
These findings do not mean that every patient must undergo the same operation. They indicate the need for careful assessment of the risk of progression, the likely effectiveness of further bladder-directed treatment, surgical fitness and the patient’s preferences. The decision should be made after reviewing the pathology, staging, previous treatment and available options.
Yes, selected patients with high-grade non-muscle-invasive bladder cancer can be managed with TURBT and bladder-directed treatment, including BCG when appropriate. However, bladder preservation is not equally suitable for every patient.
The decision depends on whether the tumour can be adequately resected, the stage and risk category, the presence of adverse pathological features, and the likelihood of achieving durable disease control with bladder-directed treatment.
For some patients, early cystectomy may offer a better oncological strategy than continuing repeated treatments with a substantial risk of progression. The objective is to avoid unnecessary major surgery while also avoiding a delay in definitive treatment when the cancer’s risk justifies it.
A tumour that returns after TURBT or intravesical treatment requires reassessment. The next step depends on whether the recurrent tumour is low-grade or high-grade, its stage, the timing of recurrence and the treatment previously received.
Persistent or recurrent high-grade disease after adequate BCG treatment may indicate that the current treatment strategy is not controlling the cancer sufficiently. The treating team must establish the nature of the recurrence and determine whether further bladder-directed treatment remains appropriate or whether radical cystectomy should be recommended.
This decision should not be based on the word ‘recurrence’ alone. The pathology, stage, previous treatment and timing of recurrence all matter.
Even after apparently successful treatment, high-grade non-muscle-invasive bladder cancer requires careful surveillance because recurrence and progression can occur.
Follow-up commonly includes cystoscopy, with urine cytology and other investigations when indicated. The surveillance schedule depends on the patient’s risk category and previous findings. Patients with high-risk disease generally need more intensive and prolonged follow-up than those with low-risk disease.
Follow-up also allows the treating team to identify new tumours, assess response to treatment and reconsider the management plan if the disease changes. Patients should attend scheduled appointments even when they have no urinary symptoms.
Feature | Low-grade disease | High-grade disease |
Appearance under microscope | Cells look less abnormal | Cells look more abnormal |
Risk of progression | Generally lower | Generally higher |
Repeat TURBT | Depends on findings and risk | Often important for selected high-grade tumours |
Intravesical treatment | Depends on risk category | BCG is important for appropriate high-risk disease |
Discussion of cystectomy | Uncommon in low-risk disease | Important for selected very high-risk cases |
Surveillance | Required | Generally more intensive for high-risk disease |
Grade alone does not determine treatment. Stage, carcinoma in situ, tumour burden, pathological features and response to previous treatment must also be considered.
Dr. Swati H. Shah is a uro-oncologist and surgical oncologist in Ahmedabad with experience in bladder cancer surgery since 2008.
Her practice includes TURBT, repeat tumour assessment, radical cystectomy, robotic radical cystectomy, pelvic lymph-node dissection and urinary reconstruction for appropriately selected patients.
For high-grade non-muscle-invasive bladder cancer, an important part of treatment planning is identifying patients who can be managed with bladder-directed treatment and those who should consider more definitive surgery.
The aim is to make a treatment decision based on the tumour’s actual risk, rather than grade alone, while considering cancer control, treatment-related risks and long-term quality of life.
Patients seeking a second opinion should bring their cystoscopy findings, TURBT operative notes, histopathology reports, relevant imaging and details of any previous intravesical treatment.
No. High-grade describes the appearance of the cancer cells, not how far the cancer has spread. High-grade tumours can remain non-muscle-invasive, although they require careful assessment because of their higher risk of progression.
No. Some patients can be treated with TURBT and intravesical therapy, including BCG when appropriate. Radical cystectomy should be discussed for selected patients with very high-risk features or disease that does not respond adequately to treatment.
Repeat TURBT may be required to remove residual tumour, confirm the stage or improve the reliability of the assessment, particularly in T1 disease or when the initial resection was incomplete or inadequately staged.
BCG is an immunotherapy placed directly into the bladder through a catheter. It stimulates a local immune response and is an important treatment for appropriate patients with high-risk non-muscle-invasive bladder cancer.
The next step depends on the timing and type of recurrence, previous BCG treatment and the patient’s overall risk. For selected patients with persistent or recurrent high-grade disease after adequate BCG, radical cystectomy should be discussed.
Yes. High-grade non-muscle-invasive bladder cancer can progress to muscle-invasive disease. The risk varies between patients, which is why appropriate treatment and close surveillance are important.
A second opinion may help clarify the pathological stage, risk factors, available treatments and reasons for recommending surgery. It should not unnecessarily delay treatment when the disease has features associated with a high risk of progression.
A 69-year-old male presented with intermittent, visible blood in his urine, a classic warning sign of underlying bladder pathology. Diagnostic imaging identified a 2 cm mass located on the right lateral wall, necessitating a precise intervention to both treat the lesion and obtain a definitive tissue diagnosis for staging.
⦿ Transurethral Resection of Bladder Tumor (TURBT)
• Procedure: Performed a complete endoscopic resection of the 2 cm right lateral bladder wall tumor.
• Staging Accuracy: Captured a targeted deep muscle biopsy to accurately determine the depth of tumor invasion.
• Safety / Blood Loss: Achieved successful intraoperative hemostasis, ensuring the patient remained hemodynamically stable throughout the procedure.
• Functional Preservation: Integrated a Double J stent placement to safeguard kidney function and maintain smooth urinary flow.
⦿ Rapid Recovery and Early Ambulation
The patient’s recovery was immediate and uneventful, with pain levels expertly managed through minimally invasive protocols. He was fully ambulatory and ready for discharge within just 24 hours of the procedure, returning home in stable condition. This proactive surgical intervention provided both a functional cure for the hematuria and a critical pathological roadmap for his future surveillance.
Visible blood in urine is a signal that demands immediate action. Through this minimally invasive endoscopic approach, we were able to completely remove the tumor and provide accurate staging, allowing this patient to return to his daily life almost immediately while securing a clear path for long-term monitoring.
The goal of radical cystectomy is to achieve complete removal of the cancer with adequate surgical margins while addressing possible spread to regional lymph nodes. Careful dissection and attention to anatomical planes are essential to ensure a thorough and safe oncological procedure.
Robotic surgery can provide a magnified 3D view, precise instrument control and enhanced dexterity, which can be particularly useful during complex pelvic cancer surgery. However, the choice of surgical approach depends on the cancer stage, anatomy, patient’s overall condition and the expertise of the surgical team.
The surgical specimen is carefully examined by the pathology team to assess the tumour, lymph nodes and surgical margins. Clear margins are an important component of complete cancer surgery.
With robotic surgery, the surgeon operates using a high-definition 3D, magnified view and specialized instruments that provide enhanced dexterity and precision. This can be particularly valuable during complex pelvic cancer surgery, where careful dissection is required around major blood vessels, nerves and other critical structures.
The procedure shown demonstrates meticulous removal of the bladder and lymph nodes as part of comprehensive cancer surgery. Robotic minimally invasive surgery may offer potential benefits such as smaller incisions, reduced blood loss, less postoperative discomfort and earlier recovery, although the suitability and benefits vary according to the cancer stage, anatomy and overall health of each patient.
Every bladder cancer patient requires an individualized treatment plan based on the tumour characteristics and stage.
This video features a patient testimonial and educational insight from Dr. Swati Shah, a renowned Robotic Uro-Oncologist and Gynecologic Cancer Surgeon. The primary focus of the video is on “Robotic Cystectomy with Neobladder,” a highly advanced surgical procedure used to treat urinary bladder cancer. When a patient’s urinary bladder is entirely removed due to cancer (a procedure called a cystectomy), a major concern is how they will pass urine afterward. The video addresses this critical question by explaining the concept of a “neobladder”—a new bladder surgically created from the patient’s own intestine, allowing them to urinate naturally without the need for an external stoma bag.
The video features a heartwarming and positive patient testimonial dedicated to Dr. Swati Shah, a highly regarded Robotic Uro-Oncologist and Gynecological Cancer Surgeon. It highlights the successful treatment of an elderly patient, who traveled from Kotvada village in the Bhavnagar district of Gujarat to seek specialized medical care. He recently underwent a complex Radical Cystectomy—a major surgical procedure to remove the urinary bladder—for the treatment of urinary bladder cancer under the expert supervision of Dr. Shah at Apollo Hospital. In the brief clip, the patient’s nephew shares their medical journey, explaining that they discovered Dr. Swati Shah’s profile online while searching for the best possible urological cancer treatment.
This video features a heartfelt patient testimonial detailing a successful bladder cancer surgery performed by Dr. Swati Shah, a highly skilled Robotic Uro-Oncologist. In the clip, a patient shares their personal recovery journey following a complex Robotic Radical Cystectomy, a major procedure where a new urinary bladder, known as a neobladder, was surgically created using advanced robotic technology. The patient explains that they underwent this operation two months prior. Although they initially felt anxious and fearful about the potential complications of such a significant medical procedure, the modern robotic approach and Dr. Shah’s expertise made the experience remarkably smooth.
Medical disclaimer: This page provides general educational information and does not replace individual medical advice. Treatment decisions should be based on the patient’s complete clinical assessment, pathology, imaging, previous treatment and applicable clinical guidelines.
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.